Who we are
OUR MISSION
Our mission is to create innovative solutions that positively impact patients, society, and the environment.
OUR VISION
We’re dedicated to promoting pharmaceutical innovation to improve lives, with a particular focus on rare diseases.
An overview of Italfarmaco
Italfarmaco is a private multinational group founded in 1938 and based in Milan, Italy. We produce high-quality medicinal specialties adhering to the highest quality standards. We are committed to improving patients’ lives and overall well-being through pioneering research and development, high-quality production, and global marketing of branded prescription and non-prescription products.
Therapeutic Areas
Here’s where our expertise brings effectiveness.
Our expertise in developing effective treatments enables us to address complex challenges in key therapeutic areas.
Evolution: how to make treatments more accessible for more patients
Pharmaceutics is a dynamic science, constantly evolving to make every medicine, formula, and application more effective. Our commitment to accessibility drives us to provide significant benefits and enable more people to access targeted and effective treatments. In our four research hubs, we focus on identifying new dosing solutions for approved drugs, repurposing reformulations, and developing APIs to deliver high-quality generic medicines to the market, ensuring that healthcare is more inclusive.
News & Highlights
Discover tha latest news and insights on Italfarmaco Group
2024 - June 28
Combines AI to increase the potential of novel histone deacetylase (HDAC) inhibitors in the non-oncological field
2023 - September 7
7 September marks World Duchenne Awareness Day (WDAD), a disease in which we as a company are particularly involved.
2022 - September 7
September 7th is World Duchenne Muscular Dystrophy Awareness Day, a disease that sees us, as a company, at the forefront of the search for a drug that can slow down its progression.
2022 - July 26
Thanks to this operation, that is subject to the approval of the competition authorities, the Group will reach 1,300 employees in Spain and 3,500 globally, with a consolidated turnover of over 1 billion euros.